Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2012

01-09-2012 | Co-infections (C Benson, Section Editor)

Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline

Authors: Carrie L. Jennings, Kenneth E. Sherman

Published in: Current HIV/AIDS Reports | Issue 3/2012

Login to get access

Abstract

HCV/HIV coinfection continues to represent a serious health issue with risk of liver disease progression and development of hepatocellular carcinoma. Pegylated interferon with ribavirin is approved for treatment but results are suboptimal and tolerability poor. First-generation HCV protease inhibitors appear to significantly improve HCV treatment response in the setting of HIV infection. Interactions with HIV protease inhibitors have been documented, but the significance of this in terms of adverse reactions and HCV or HIV viral breakthrough remains uncertain. Next generation agents hold the promise of even better efficacy, with improved dosing schedules and perhaps decreased risk of drug:drug interactions.
Literature
1.
Sherman KE, Thomas DL, Chung RT. Human immunodeficiency virus and liver disease forum 2010: conference proceedings. Hepatology. 2011;54:2245–53.PubMedCrossRef
2.
Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr. 2001;26:340–4.PubMedCrossRef
3.
Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054–8.PubMedCrossRef
4.
Sherman KE. HCV and HIV: a tale of two viruses. Rev Gastroenterol Disord. 2004;4 Suppl 1:S48–54.PubMed
5.
Sulkowski MS, Cheever L, Spach DH. A guide for evaluation and treatment of hepatitis C in adults coinfected with HIV. In: U.S. Department of Health and Human Services Health Resources and Services Administration; 2011.
6.
Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–9.PubMedCrossRef
7.
Torriani FJ, Chung RT. Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. ACP journal club 2005;142:A12; author reply A3.
8.
Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Am Med Assoc. 2004;292:2839–48.CrossRef
9.
Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, et al. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother. 2009;63:1256–63.PubMedCrossRef
10.
Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat. 2007;14:239–48.PubMedCrossRef
11.
•• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16. This paper describes the phase 3 pivotal trial that led to approval of telaprevir for HCV monoinfection treatment in treatment-naive patients.PubMedCrossRef
12.
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–24. This phase 3 study established that response-guided therapy represents a rational and highly efficacious methodology for the treatment of HCV using newer DAA agents.PubMedCrossRef
13.
•• Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206. This study described the phase 3 pivotal trial that led to approval of boceprevir for HCV monoinfection treatment in treatment-naive patients.PubMedCrossRef
14.
Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.PubMedCrossRef
15.
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.PubMedCrossRef
16.
Montaudie H, Passeron T, Cardot-Leccia N, Sebbag N, Lacour JP. Drug rash with eosinophilia and systemic symptoms due to telaprevir. Dermatology. 2010;221:303–5.PubMedCrossRef
17.
Sulkowski MS, Pol S, Cooper, C, Fainboim H, Slim J, Rivero A, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV co-infected patients: End of treatment (Week 48) interim results. In: CROI. Seattle, WA; 2012.
18.
Dieterich D, Soriano V, Sherman KE, Girard P-M, Rockstroh J, Adiwijaya B, et al. Telaprevir in combination with pegylated interferon alfa 2a + ribavirin in HCV/HIV coinfected patients: A 24-week treatment interim analysis. In: 19th Conference on Retroviruses and Opportunistic Infections (CROI); 2012:Abs. 46.
19.
Kasserra C, Hughes E, Treitel M, Gupta S, O’Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug–drug Interactions. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston; 2011.
20.
Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11:179–85.PubMed
21.
Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012.
22.
Dianzani F, Rozera G, Abbate I, et al. Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. J Interferon Cytokine Res. 2008;28:1–3.PubMedCrossRef
23.
van Heeswijk R, Vandevoorde A, Boogaerts G, Vangeneugden T, de Paepe E, Polo R, et al. Pharmacokinetic Interactions between ARV Agents and the Investigational HCV Protease Inhibitor TVR in Healthy Volunteers. In: CROI. Boston; 2011.
24.
Sherman KE, Fleischer R, Laessig K, Murray J, Tauber W, Birnkrant D. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology. 2007;46:2014–20.PubMedCrossRef
25.
Zamor PJ, Rouster S, Sherman KE. HCV NS3 mutations in HCV-HIV coinfected and HCV monoinfected subjects. In: AASLD. Boston; 2010.
26.
Sherman KE, Sulkowski MS, Zoulim F, et al. Follow-up of Svr durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis of the extend study. Hepatology. 2011;54:485a–6a.CrossRef
27.
Brass C, Barnard RJO, Howe JA, et al. Sustained virologic response and boceprevir resistance-associated variants observed in patients infected with Hcv genotype 1a/1b when treated with boceprevir plus peginterferon alfa-2b/ribavirin. J Hepatol. 2011;54:S471–2.CrossRef
28.
Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.PubMedCrossRef
29.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.PubMedCrossRef
30.
Abu Dayyeh BK, Gupta N, Sherman KE, de Bakker PIW, Chung RT. A5178 ACTG. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One 2011;6.
31.
Rallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23–9.PubMedCrossRef
32.
Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (Boc) combination therapy. Gastroenterology. 2011;140:S941-S.
33.
Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. In: EASL. Berlin; 2011.
34.
Crabbe R, Vuagniaux G, Dumont JM, Nicolas-Metral V, Marfurt J, Novaroli L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs. 2009;18:211–20.PubMedCrossRef
35.
Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology. 2008;47:817–26.PubMedCrossRef
36.
Flisiak R, Pawlotsky JM, Crabbe R, et al. Once daily alisporivir (Deb025) plus PegIFNalfa2a/Ribavirin results in superior sustained virologic response (Svr24) in chronic hepatitis C genotype 1 treatment naive patients. J Hepatol. 2011;54:S2-S.
37.
Flisiak R, Jaroszewicz J, Flisiak I, Łapiński T. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs. 2012;21:375–82.PubMedCrossRef
38.
Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–24.PubMedCrossRef
Metadata
Title
Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline
Authors
Carrie L. Jennings
Kenneth E. Sherman
Publication date
01-09-2012
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 3/2012
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-012-0122-z

Other articles of this Issue 3/2012

Current HIV/AIDS Reports 3/2012 Go to the issue

Co-infections (C Benson, Section Editor)

New Insights in the Prevention, Diagnosis, and Treatment of Cryptococcal Meningitis

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Osteoporosis and Bone Health in HIV

Co-infections (C Benson, Section Editor)

Human Papillomavirus Vaccines: Where Do They Fit in HIV-Infected Individuals?

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Smoking and HIV: Prevalence, Health Risks, and Cessation Strategies

Co-infections (C Benson, Section Editor)

Treatment of Latent Tuberculosis Infection in HIV: Shorter or Longer?

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

HIV-Specific Immune Dysregulation and Atherosclerosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits